neurobiology
(2)
Tom Large
Tom Large is the CEO and co-founder of Blue Oak Pharmaceuticals, a Waltham, Massachusetts startup hunting for the next generation of medicines for brain disorders. A neurobiologist by training, he spent two decades inside big pharma - leading neuroscience research at Eli Lilly and running preclinical research and translational medicine at Sunovion - before launching Blue Oak in 2016 to chase drugs with genuinely new mechanisms for bipolar depression, schizophrenia and treatment-resistant depression. His teams pioneered a target-agnostic approach to CNS drug discovery, and he later partnered with AI specialist Exscientia to design 'bispecific' small molecules that hit two targets at once.
Andrew Huberman
Andrew Huberman is a tenured professor of neurobiology and ophthalmology at Stanford University School of Medicine and the host of the Huberman Lab podcast - regularly ranked the #1 health and science podcast in the world with over 400 episodes. His Stanford lab investigates visual system repair, neural plasticity, and stress resilience, publishing in Nature, Science, and Cell. A former skateboarder who once wrote for Thrasher magazine and lobbied the Palo Alto city council to build a skate park at age 13, Huberman translates complex neuroscience into actionable protocols for millions of listeners globally.